This article is more than 5 years old. Information may no longer be current.
CV safety associated with diabetes therapies examined in two new trials
Click Here to Manage Email Alerts
The cardiovascular safety of diabetes treatments has long been questioned by the medical community, in particular the effect of such drugs on the risk for cardiovascular mortality, myocardial infarction and stroke. Now, two new trials addressed the cardiovascular safety of DPP-IV inhibitors, and the findings have created discussion among endocrinologists and cardiologists.
Deepak L. Bhatt
The SAVOR-TIMI 53 and EXAMINE trials were highlighted at the annual European Society of Cardiology (ESC) Congress and European Association for the Study of Diabetes (EASD) meeting and published in The New England Journal of Medicine. In SAVOR-TIMI 53, saxagliptin (Onglyza, AstraZeneca/Bristol-Myers Squibb) added to standard care neither reduced nor increased risk for ischemic events as compared with placebo in patients with type 2 diabetes at high CV risk. In EXAMINE, alogliptin (Nesina, Takeda Pharmaceuticals) added to standard care did not increase major adverse CV event rates as compared with placebo in patients with type 2 diabetes and recent acute coronary syndrome.
Endocrine Today spoke with experts, including Deepak L. Bhatt, MD, MPH, to gain insight into these trials and how they will affect clinical practice.
Find out more by reading this month's cover story in our print issue online.